Total Payments
$5,755
2024 Payments
$1,171
Companies
41
Transactions
371
Medicare Patients
7,290
Medicare Billing
$731,440
Payment Breakdown by Category
Food & Beverage$5,738 (99.7%)
Education$16.24 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,738 | 370 | 99.7% |
| Education | $16.24 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $967.82 | 76 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $751.19 | 39 | $0 (2024) |
| Genentech USA, Inc. | $508.72 | 37 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $448.80 | 31 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $407.99 | 27 | $0 (2024) |
| United Therapeutics Corporation | $257.22 | 13 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $215.66 | 9 | $0 (2024) |
| GENZYME CORPORATION | $214.19 | 11 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $196.89 | 15 | $0 (2021) |
| Mylan Specialty L.P. | $191.88 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,171 | 66 | AstraZeneca Pharmaceuticals LP ($205.26) |
| 2023 | $933.94 | 51 | GlaxoSmithKline, LLC. ($179.94) |
| 2022 | $820.32 | 50 | AstraZeneca Pharmaceuticals LP ($202.47) |
| 2021 | $586.44 | 36 | United Therapeutics Corporation ($85.61) |
| 2020 | $227.46 | 16 | GlaxoSmithKline, LLC. ($66.24) |
| 2019 | $706.70 | 52 | GlaxoSmithKline, LLC. ($180.49) |
| 2018 | $695.63 | 50 | GlaxoSmithKline, LLC. ($117.19) |
| 2017 | $612.72 | 50 | Genentech USA, Inc. ($96.41) |
All Payment Transactions
371 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: RESPIRATORY | ||||||
| 11/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Cardiology | ||||||
| 11/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/28/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/24/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: Cardiology | ||||||
| 10/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: RESPIRATORY | ||||||
| 10/16/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: IMMUNOLOGY | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Respiratory | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 10/01/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $2.48 | General |
| Category: RESPIRATORY | ||||||
| 09/26/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Cardiology | ||||||
| 09/23/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Respiratory | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Respiratory | ||||||
| 09/16/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $31.90 | General |
| Category: Narcoplepsy | ||||||
| 09/10/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: RESPIRATORY | ||||||
| 09/09/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 09/03/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Respiratory | ||||||
| 08/20/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Respiratory | ||||||
| 08/19/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,806 | 2,580 | $554,053 | $163,429 |
| 2022 | 24 | 1,937 | 3,211 | $639,625 | $184,537 |
| 2021 | 20 | 1,743 | 2,987 | $572,432 | $178,899 |
| 2020 | 26 | 1,804 | 3,267 | $682,404 | $204,575 |
Total Patients
7,290
Total Services
12,045
Medicare Billing
$731,440
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 311 | 609 | $127,890 | $53,629 | 41.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 535 | 865 | $131,480 | $49,659 | 37.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 182 | 273 | $35,490 | $15,978 | 45.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 102 | 103 | $28,325 | $9,669 | 34.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 46 | $19,550 | $6,000 | 30.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 57 | 57 | $12,768 | $4,275 | 33.5% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 56 | 60 | $45,350 | $3,560 | 7.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 173 | 200 | $37,000 | $3,505 | 9.5% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 118 | 131 | $36,025 | $2,883 | 8.0% |
| 31500 | Emergent insertion of breathing tube into windpipe using an endoscope | Facility | 2023 | 24 | 25 | $10,800 | $2,574 | 23.8% |
| 36800 | Insertion of tube connecting vein to vein for hemodialysis | Facility | 2023 | 21 | 21 | $10,500 | $1,897 | 18.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 21 | $4,725 | $1,732 | 36.7% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 30 | 30 | $6,000 | $1,713 | 28.6% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 20 | 20 | $18,000 | $1,383 | 7.7% |
| 71271 | Low dose ct scan of chest for lung cancer screening | Office | 2023 | 16 | 16 | $4,000 | $1,330 | 33.2% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2023 | 16 | 16 | $12,800 | $1,009 | 7.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 20 | 23 | $3,450 | $926.80 | 26.9% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 18 | 21 | $2,625 | $674.94 | 25.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 19 | 19 | $3,800 | $539.22 | 14.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 11 | 11 | $550.00 | $312.84 | 56.9% |
| 71045 | X-ray of chest, 1 view | Office | 2023 | 12 | 13 | $2,925 | $177.68 | 6.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 650 | 1,566 | $238,032 | $82,067 | 34.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 253 | 469 | $98,490 | $34,856 | 35.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 185 | 273 | $35,490 | $15,902 | 44.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 134 | 138 | $37,950 | $13,329 | 35.1% |
About Dr. Michael Munday, DO
Dr. Michael Munday, DO is a Pulmonary Disease healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1710019930.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Munday, DO has received a total of $5,755 in payments from pharmaceutical and medical device companies, with $1,171 received in 2024. These payments were reported across 371 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($5,738).
As a Medicare-enrolled provider, Munday has provided services to 7,290 Medicare beneficiaries, totaling 12,045 services with total Medicare billing of $731,440. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Memphis, TN
- Active Since 03/12/2007
- Last Updated 02/17/2020
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1710019930
Products in Payments
- TRELEGY ELLIPTA (Drug) $517.96
- DUPIXENT (Biological) $345.93
- Xolair (Biological) $270.40
- UPTRAVI (Drug) $244.32
- Esbriet (Biological) $238.32
- NUCALA (Biological) $196.98
- BREZTRI (Drug) $194.98
- ACTHAR (Biological) $181.73
- STIOLTO RESPIMAT (Drug) $176.65
- WAKIX (Drug) $165.62
- TEZSPIRE (Biological) $163.15
- OFEV (Drug) $153.79
- Arikayce (Drug) $152.16
- FASENRA (Biological) $143.61
- TYVASO (Drug) $139.08
- ANORO (Drug) $109.51
- OPSUMIT (Drug) $106.68
- ZERBAXA (Drug) $101.42
- ORENITRAM (Drug) $97.31
- YUPELRI (Drug) $96.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Memphis
Anthony Mattox, D.o, D.O
Pulmonary Disease — Payments: $21,781
Pulmonary Disease $21,781
Dr. Nathan Wilds, Md, MD
Pulmonary Disease — Payments: $20,941
Pulmonary Disease $20,941
Jeffrey Wright, M.d, M.D
Pulmonary Disease — Payments: $15,147
Pulmonary Disease $15,147
Robert Aguillard, Md, MD
Pulmonary Disease — Payments: $11,075
Pulmonary Disease $11,075
Roy Fox, Md, MD
Pulmonary Disease — Payments: $10,189
Pulmonary Disease $10,189
Dr. Kimberly Marsh, M.d, M.D
Pulmonary Disease — Payments: $9,654
Pulmonary Disease $9,654